4.71M
deaths associated with bacterial AMR globally in 2021
WHO / GBD 2021 Antimicrobial resistance · Diagnostic intelligence
Interpret resistance.
Inform treatment.
ResistIQ Diagnostics is a South African company developing antimicrobial-resistance diagnostics and clinical decision-support tools to help interpret bacterial genomic evidence.
In development · Pre-market · Not for clinical use
complex biological evidence
INTERPRETED OUTPUT
concept view
Evidence linked.
A structured interpretation brings multiple resistance signals into one clinical view.
Evidence context
Illustrative product concept. Not a clinical result.
clinically meaningful insight
The scale of the problem
Antimicrobial resistance is already changing the odds.
Global burden data makes the urgency difficult to ignore.
1.14M
deaths directly attributable to bacterial AMR in 2021
WHO / GBD 20211 in 6
laboratory-confirmed bacterial infections were antibiotic-resistant in 2023
WHO, 2026 AMR fact sheetSub-Saharan Africa experienced the highest AMR mortality rates.
WHO Regional Office for Africa01
The decision gap
Detection is only the beginning.
Genomic data can reveal resistance evidence. The harder problem is translating that evidence into something useful when a clinical decision has to be made.
02
Our approach
From biological evidence
to clinical intelligence.
01 · DETECT
Start with the biological evidence.
Identify genomic resistance determinants and relevant sequence features from microbial data.
Evidence first. Interpretation second.
03
Why it matters
Data only matters
when it can change
a decision.
ResistIQ is being built around the gap between detecting resistance evidence and interpreting what that evidence means in a diagnostic workflow.
Not another data dump.
A clearer interpretation.
04
Science & development
Build the evidence.
Then earn the claim.
ResistIQ Diagnostics is in development. Clinical validity, clinical utility and regulatory approval have not yet been established. Our work is intended to complement phenotypic antimicrobial susceptibility testing (AST). It does not replace phenotypic AST or diagnose directly from patient samples.
Software architecture and genomic analysis workflow under active development.
Testing against curated genomic datasets and phenotype-linked reference data.
Future prospective validation and real-world diagnostic studies will be required.
Future pre-market regulatory and quality-system development.
05
Built for the diagnostic ecosystem
Clarity for the people
who have to act.
Clinical laboratories
Translate genomic resistance evidence into a structured interpretation layer.
Stewardship teams
Bring resistance evidence into antimicrobial decision-making workflows.
Clinicians
Support more informed treatment discussions with evidence-linked insight.
Research partners
Build, test and challenge the evidence base behind genomic interpretation.
The company
Diagnostics built around interpretation.
ResistIQ Diagnostics is a South African biotechnology company developing antimicrobial-resistance diagnostics and clinical decision-support tools. Our aim is to make complex microbial resistance evidence easier to interpret within future diagnostic workflows.
Our official website is resistiq.co.za. ResistIQ Diagnostics is independent of the unrelated Resistance IQ at resistiq.com.
Work with us Collaboration
A more resilient tomorrow will be built together.
We’re interested in conversations with diagnostic laboratories, AMR researchers, clinical collaborators, sequencing partners and organisations working on antimicrobial resistance.
ResistIQ Diagnostics is an early-stage research and development venture. The platform is not currently approved for clinical diagnosis or treatment selection and should not be used for patient-care decisions.